deCODE Genetics, A Subsidiary Of Amgen, Has Published A Study In The New England Journal Of Medicine, On Actionable Genotypes Detected In The Icelandic Population And Their Association With Lifespan
Portfolio Pulse from Benzinga Newsdesk
deCODE Genetics, a subsidiary of Amgen, published a study in the New England Journal of Medicine on actionable genotypes in the Icelandic population. The study found that 4% of Icelanders carry genotypes associated with serious diseases, which can significantly shorten lifespan. The Icelandic government is motivated by these findings to pursue a nationwide precision medicine effort. Amgen's deCODE has discovered genetic risk factors for many diseases and aims to improve disease diagnosis, treatment, and prevention.
November 15, 2023 | 2:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's subsidiary deCODE Genetics' study on actionable genotypes may enhance the company's reputation in precision medicine and could lead to increased interest in its genomics-related services.
The publication of a significant study by deCODE Genetics, which is owned by Amgen, could positively impact Amgen's stock in the short term. The study's implications for precision medicine and potential disease prevention are likely to be viewed favorably by investors, as they may lead to new opportunities for Amgen in the healthcare market. The direct association with improving patient outcomes and the potential for reducing disease burden could result in increased demand for Amgen's genomics services, thereby potentially increasing revenues.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80